RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

RemeGen Co., Ltd.

荣昌生物制药（烟台）股份有限公司 specializes in the development and commercialization of innovative drugs, specifically in the fields of autoimmune diseases and oncology, with products such as Telitacicept and Disitamab Vedotin.

荣昌生物制药（烟台）股份有限公司

RemeGen Biosciences | 6,932 followers on LinkedIn. Science with a purpose: creating innovative medicines to serve patients suffering from serious illnesses  | RemeGen Biosciences is a biopharmaceutical company, focusing on the discovery and development of innovative medicines for the treatment of cancer and autoimmune diseases, based in South San Francisco, California, and Rockville, Maryland. By leveraging our deep insights into oncology and immunology, advanced protein engineering/design technologies, and extensive knowledge in clinical development, our vision is to uncover the novel therapeutic targets and develop the best-in-class and first-in-class biotherapeutics for the patients with significant unmet medical needs. RemeGen Bioscience is a wholly owned subsidiary of RemeGen Co., a global pharmaceutic company specialized in autoimmune, oncology and ophthalmic diseases.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	11.32M -			1.42B -	767.77M 46.08%	1.08B 41.05%
cost of revenue	8.93M -			67.16M -	269.94M 301.92%	257.27M 4.69%
gross profit	2.39M -			1.36B -	497.84M 63.31%	825.68M 65.85%
selling and marketing expenses		621K -	24.18M 3,793.72%	262.97M 987.54%	440.70M 67.59%	775.19M 75.90%
general and administrative expenses	9.37M -	32.78M 249.83%	217.62M 563.91%	219.84M 1.02%	272.54M 23.97%	304.23M 11.63%
selling general and administrative expenses	9.37M -	33.40M 256.46%	241.80M 623.96%	482.81M 99.67%	713.24M 47.73%	1.09B 52.45%
research and development expenses	216.44M -	352.07M 62.66%	465.82M 32.31%	710.97M 52.63%	982.08M 38.13%	1.31B 33.01%
other expenses	8.05M -	3.28M 59.23%	-70.38M 2,244.49%	-140.13M 99.09%	-143.40M 2.34%
cost and expenses	242.79M -	388.75M 60.12%	637.24M 63.92%	1.12B 75.89%	1.82B 62.55%	2.61B 43.05%
operating expenses	233.86M -	388.75M 66.23%	637.24M 63.92%	1.05B 65.35%	1.55B 47.29%	2.35B 51.36%
interest expense	40.05M -	43.79M 9.32%	29.23M 33.26%	5.32M 81.79%	6.76M 26.94%
ebitda	-208.72M -	-343.85M 64.75%	-590.88M 71.84%	402.39M 168.10%	-806.70M 300.47%	-1.37B 70.25%
operating income	-231.35M -	-386.63M 67.11%	-668.55M 72.92%	281.92M 142.17%	-993.07M 452.25%	-1.55B 55.62%
depreciation and amortization	22.64M -	42.77M 88.93%	77.67M 81.58%	120.47M 55.12%	186.37M 54.70%	172.02M 7.70%
total other income expenses net	-38.59M -	-43.66M 13.12%	-29.27M 32.94%	-5.66M 80.65%	-5.76M 1.77%	34.16M 692.69%
income before tax	-269.95M -	-430.28M 59.39%	-697.82M 62.18%	276.26M 139.59%	-998.83M 461.56%	-1.51B 51.30%
income tax expense	-1.46M -	43.66M 3,085.98%	29.27M 32.94%	5.66M 80.65%	-993K 117.53%
net income	-268.49M -	-473.94M 76.52%	-727.09M 53.42%	276.26M 137.99%	-997.84M 461.20%	-1.51B 51.45%
weighted average shs out	478.36M -	478.36M 0%	408.15M 14.68%	487.44M 19.43%	530.12M 8.76%	539.72M 1.81%
weighted average shs out dil	478.36M -	478.36M 0%	408.15M 14.68%	487.44M 19.43%	531.15M 8.97%	539.72M 1.61%
eps	-0.56 -	-0.99 76.79%	-1.78 79.80%	0.57 132.02%	-1.88 429.82%	-2.80 48.94%
epsdiluted	-0.56 -	-0.99 76.79%	-1.78 79.80%	0.57 132.02%	-1.88 429.82%	-2.80 48.94%

9995

COM:REMEGEN

荣昌生物制药（烟台）股份有限公司

Last Close

18.06

22/11 03:04

Market Cap

14.40B

Beta: -

Volume Today

1.05M

Avg: -

Preview